SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
| | | |
| Date of Report (Date of earliest event reported): | | December 19, 2005 |
| |
| BARR PHARMACEUTICALS, INC. |
| |
| (Exact Name of Registrant as Specified in its Charter) |
| | | | | |
| Delaware | | 1-9860 | | 42-1612474 |
| |
(State or Other
Jurisdiction of
Incorporation) | | (Commission
File Number) | | (I.R.S. Employer
Identification No.) |
| | | |
| 400 Chestnut Ridge Road, Woodcliff, NJ | | 07677 |
| |
| (Address of Principal Executive Offices) | | (Zip Code) |
| | | |
| Registrant’s telephone number, including area code: | | (201) 930-3300 |
| |
(Former Name or Former Address, if Changed Since Last Report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| | | |
| o | | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| | | |
| o | | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| | | |
| o | | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| | | |
| o | | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
TABLE OF CONTENTS
Item 7.01 — Regulation FD Disclosure
Today Barr Pharmaceuticals, Inc. issued a press release announcing the resignation of Dr. Carole S. Ben-Maimon, President and Chief Operating Officer of Duramed Research, Inc. A copy of the press release is attached to this current report as Exhibit 99.1 and is incorporated herein by reference .
Item 9.01 – Financial Statements and Exhibits
(c) Exhibits
| | | | | | | |
| | | | 99.1 | | | Press release issued by Barr Pharmaceuticals, Inc. dated December 19, 2005, announcing the resignation of Dr. Carole Ben-Maimon. |
